Changeflow GovPing Healthcare & Life Sciences Preeclampsia Risk and IVF Cycles Guidance
Priority review Guidance Added Final

Preeclampsia Risk and IVF Cycles Guidance

Email

Summary

The Food and Drug Administration (FDA) has issued new guidance regarding the risk of preeclampsia associated with in vitro fertilization (IVF) cycles. This guidance aims to inform healthcare providers and patients about potential risks and management strategies.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The FDA has released guidance addressing the association between in vitro fertilization (IVF) cycles and an increased risk of preeclampsia. The document outlines current understanding of this risk, potential contributing factors, and recommendations for monitoring and management during pregnancy.

Healthcare providers should familiarize themselves with this guidance to counsel patients undergoing or considering IVF about potential pregnancy complications. Patients should discuss these risks with their fertility specialists and obstetricians to ensure appropriate prenatal care and monitoring. While this is guidance and not a binding rule, adherence is recommended to ensure patient safety and informed consent.

What to do next

  1. Review FDA guidance on preeclampsia risk and IVF cycles
  2. Incorporate updated information into patient counseling regarding IVF and pregnancy risks
  3. Ensure appropriate monitoring protocols are in place for pregnant patients who have undergone IVF

Archived snapshot

Mar 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Substantive
Document ID
FDA-2026-P-3169-0004
Docket
FDA-2026-P-3169-0004

Who this affects

Applies to
Drug manufacturers Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers
Activity scope
Clinical Trial Reporting Drug Labeling
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!